You searched for "carcinomas"

142 results found

Patterns of relapse and implications for post-nephrectomy surveillance in patients with high-risk NCC-RCC

The natural history of non-clear cell renal cell carcinoma (NCC-RCC) post-nephrectomy with curative intent remains poorly defined. The surveillance protocols are largely dependent on guidelines followed for clear cell RCC (CC-RCC). In this study, the authors evaluated the relapse patterns...

Boosting the immune response to Bacillus Calmette-Guérin

In this issue of European Urology, Buisan et al. report early clinical and immunological outcomes of subcutaneous priming with the non-live mycobacterium tuberculosis RUTI vaccine prior to intravesical Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer (NMIBC). The phase...

Urology: The Last Review - Rapid revision for FEBU and board exams

Urology: The Last Review is an invaluable resource for those revising for Fellow of the European Board of Urology (FEBU) and board exams. The book begins by diving into paediatric urology, with a thorough look into common congenital anomalies and...

Benign upper tract abnormalities

Case 1 A 28-year-old lady has been referred to your clinic with right loin pain. She has no significant past medical history but mentions that she and her partner have been trying to get pregnant. She has an US renal...

Dogs and humans share a bladder cancer biomarker: a new discovery that opens doors for early detection and treatment

A new scientific study has identified a new molecular biomarker that could help doctors detect aggressive early-stage bladder cancer, such as high-grade non-muscle invasive bladder cancer (NMIBC), in both dogs and humans. This discovery advances our knowledge of how aggressive...

Management of stage 1 non-seminomatous germ cell tumours

Testicular cancer (TC) is the most successfully treated solid tumour, achieving a cure rate of 90-95% [1-3]. Testicular cancer is relatively rare with an incidence of 2207 cases in the UK in 2014 [4] and yet is the most common...

Recent developments in bladder cancer – MIBC

This article takes a look back over recent years at new innovations and developments relating to muscle-invasive bladder cancer (MIBC) specifically, and will also touch upon what the future may hold. This article is also written as a continuation of...

Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder

Patients with high-risk non-muscle invasive bladder cancer (NMIBC) that have failed Bacillus Calmette-Guérin (BCG) treatment are a difficult group to treat, and many may not be suitable for the preferred treatment option of radical cystectomy. Bladder-preserving treatments for BCG-unresponsive high-risk...

Model to predict malignancy among Bosniak III cysts

This retrospective study over a 15-year period is to identify independent predictors of malignancy in Bosniak III (BIII) renal lesions and to build a prediction model based on identifiable clinical variables. These cysts, characterised by contrast-enhanced computed tomography (CECT), have...

Cryotherapy for small renal masses: better than surveillance?

With the rapid rise in incidental small renal mass detection, some of which have malignant potential, comes the need to either survey or treat these masses safely and with minimal morbidity. This large series of 147 patients with 171 masses,...

Outcomes of sarcomatoid differentiation in urothelial carcinoma

Sarcomatoid differentiation is a rare variant of urothelial carcinoma (UC) seen in 0.6% of cases. Its response to neo-adjuvant chemotherapy (NAC) has not been well reported. The authors have done a retrospective analysis of patients undergoing cystectomy between 1995 and...

Phase two trial of SAbR for primary RCC

A study focused on stereotactic ablative radiotherapy (SAbR) as a treatment for primary renal cell carcinoma (RCC) has yielded significant findings. The primary objective of the study was successfully met, demonstrating a 94% local control rate at one year among...